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The androgen receptor (AR) is a ligand activated transcription factor and member of the steroid hormone receptor (SHR)
subfamily of nuclear receptors. In the early stages of prostate carcinogenesis, tumour growth is dependent on androgens,
and AR directly mediates these eﬀects by modulating gene expression. During transcriptional regulation, the AR recruits
numerous cofactors with acetylation-modifying enzymatic activity, the best studied include p300/CBP and the p160/SRC family
of coactivators. It is known that recruitment of histone acetyltransferases (HATs) and histone deacetylases (HDACs) is key in fine-
tuning responses to androgens and is thus likely to play a role in prostate cancer progression. Further, these proteins can alsomodify
the AR itself. The functional consequences of AR acetylation, the role of modifying enzymes in relation to AR transcriptional
response, and prostate cancer will be discussed.
1. Introduction
The androgen receptor (AR), a ligand-activated transcription
factor and member of the steroid hormone subfamily of
the nuclear receptor (NR) superfamily, mediates androgen
signalling in the cell. The AR is the only NR that is coded on
the X-chromosome, thus males carrying a disease-associated
mutation in the gene will be hemizygous and express the
disease phenotype. The most prevalent AR-associated disease
is prostate cancer, the fifth most commonly diagnosed cancer
in the world and second most common cancer among men
[1]. The prostate is a gland situated below the bladder,
surrounding the urethra. The main function of the prostate
is the secretion of components of the seminal fluid, hence, it
plays a role in male fertility [2]. Prostate growth is dependent
upon androgens, primarily testosterone and its more potent
and physiologically active metabolite dihydrotestosterone
[3, 4].
The AR is around 919 amino acids long and has distinct
structural and functional domains [3, 5] (Figure 1). The
N-terminal domain of the receptor is highly flexible, with
minimal secondary structure that upon protein-protein
interactions can become more structured [6]. The central
DNA-binding domain (DBD) is arranged into three alpha
helices organised into two separate zinc finger-like motifs
co-ordinated by eight cysteine residues. These helices are
important in the recognition of specific DNA sequences,
termed androgen response elements (AREs), and DNA-
dependent dimerisation of the receptor [3, 7]. The ligand-
binding domain (LBD) is situated in the AR C-terminal
domain, is important in recognition and docking of andro-
gens, and has been characterised by crystallography [8, 9].
Two transactivation domains exist in the AR: activation
function-1 (AF1), situated in the N-terminal domain, and
AF2, which is located in the LBD. Unlike other SHRs, and
the majority of NRs, the main transactivation potential lies
not within the LBD but within the N-terminal domain of the
AR [6, 10–12].
The molecular events leading to AR-regulated transcrip-
tion are outlined in Figure 2. In the absence of androgens,
the AR is located in the cytoplasm, in a complex with
heat-shock and heat-shock-related proteins. Upon diﬀusion
of androgen into the cell, the globular C-terminal domain
of the receptor accepts ligand, and subsequent structural
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Figure 1: Schematic representation of the human androgen
receptor (AR). The N-terminal domain (NTD) contains activation
function-1 (AF1), which is the major region important in tran-
scriptional activation. The central DNA-binding domain (DBD)
is coordinated by two zinc finger motifs and recognises specific
androgen response elements. The ligand-binding domain (LBD),
situated in the C-terminus, is structurally well characterised and
contains the ligand-dependent transactivation domain, AF2. The
flexible hinge region connects the structured DBD and LBD and
contains both a nuclear localisation sequence and acetylation motif.
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Figure 2: Role of acetylation in AR-regulated transcription. In
general terms, ligand-dependent transcriptional activation by the
AR can be described as follows: (1) ligand-bound AR dissociates
from cytoplasmic heat-shock complexes and enters the nucleus. (2)
AR binds to specific DNA sequences termed androgen response
elements (AREs) and recruits members of the basal transcriptional
apparatus. (3) AR recruits a variety of coregulators, which may
serve to provide “platforms” for additional coregulator recruitment,
regulate the architecture of chromatin directly, and ultimately
intensify transcription from target genes. HATs function at a variety
of stages including (i) direct acetylation of AR, (ii) acetylation
of chromatin, and (iii) acetylation of other factors involved in
transcriptional regulation. See text for details.
rearrangements result in dissociation of heat-shock proteins
and the exposure of a nuclear localisation sequence (NLS)
situated in the hinge region [3]. Nuclear AR binds to
AREs located throughout the genome and recruits a variety
of cofactors including members of the basal transcription
complex and proteins with enzymatic activities such as
HATs and HDACs. The formation and identities of these
diverse multiprotein complexes result in tight transcriptional
regulation of a variety of genes involved in prostate growth,
maintenance, and diﬀerentiation [6, 13, 14].
In the following review, the impact of acetylation on
AR signalling will be discussed. First, modulation of AR
activity by direct acetylation will be examined followed by
the role of coregulator proteins with HAT/HDAC activity in
AR transcriptional complexes. Finally, the role of acetylation
in prostate cancer formation/progression and the application
of therapies will be discussed.
2. Androgen Receptor Acetylation
The AR polypeptide has a well-defined structure/function
organisation. Increased sophistication and application of
bioinformatic tools, the ability to produce high-quality
recombinant proteins, and generation of modification-
specific monoclonal antibodies have aided the identification
of multiple AR modifications. It is well known that the
AR exists as a phosphoprotein, and its function is tightly
regulated by residue-specific modification by a variety of
kinases [15], but only relatively recently has a link been
established between direct AR acetylation and protein
function. In 2000, the Pestell laboratory identified a short
motif (630KLKK633) within the hinge region of AR that
has characteristics of an acetylation motif (RXKK) and is
conserved between mouse, rat, and human AR (Figure 1)
[16]. Using 14C-labelled acetate and recombinant GST-AR
fragments, they were able to show that AR was acetylated
by p300 and p300/cAMP-response element-binding protein-
associated factor (P/CAF) in vitro, and further immuno-
precipitation experiments confirmed that AR was acetylated
by these factors in vivo [16]. Combining a peptide-based
approach with mass spectrometry, the group mapped the
region of acetylation to the AR hinge region (amino acids
623–640) and specifically the KLKK motif and showed that
mutation of this motif resulted in a drastically attenuated
response to hormone. Furthermore, p300 and P/CAF were
unable to potentiate mutant AR activity to the same degree
as wild-type, suggesting that acetylation is required for
maximal activation [16].
Elegant studies by the same laboratory using acetylation-
mimic/gain-of-function mutants confirmed that acetylation
plays a key role in AR transactivation with functional
consequences; such mutants interacted to a greater extent
with p300 than wild-type receptor and enhanced prostate
cancer cell growth on soft agar and in xenografts [17,
18]. Interestingly, AR acetylation mimics showed reduced
interactions with proteins with histone deacetylase activ-
ity (HDAC1) and also transcriptional corepressors (NCoR
(Nuclear receptor CoRepressor), Smad3). It is known that
p300 can act as a molecular scaﬀold, recruiting additional
coactivators that may modulate the transcriptional response.
As acetylation-mimic mutants interacted with p300 to a
greater extent than wild-type AR, the authors performed
additional cotransfection experiments to test a panel of coac-
tivators. Indeed, it was found that these coactivators could
activate acetylation mimics to a greater extent, presumably
via increased p300/AR interaction [17].
In addition to p300 and P/CAF, a third protein has been
identified that directly acetylates AR, termed Tat-interactive
protein, 60 kDa (TIP60) [19]. Originally identified in a yeast
two-hybrid screen using domain fragments of AR as bait,
TIP60 was shown to interact with the AR-LBD [20]. In
this assay, no interaction was observed between TIP60 and
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AR N-terminal and DNA-binding domains suggesting that
TIP60 may be involved in ligand-dependent transactivation
of the AR; however, this interaction is only stabilised in the
presence of ligand rather than ligand dependent per se [20].
Further characterisation indicated that TIP60 coactivated AR
in several cell lines, including the prostate cancer cell line
LNCaP and interacts with and augments activity of several
other SHRs (progesterone receptor, oestrogen receptor α
and β, and glucocorticoid receptor) [20, 21]. Interaction
with AR is dependent on an LXXLL motif present in the
C-terminal domain of TIP60, mutation of which results
in abolition of both interaction and coactivation [21].
Previous research had determined that TIP60 contains an
HAT domain and acetylates histone proteins H2A, H3,
and H4 [22]. Using combined 3H-acetyl incorporation and
immunoprecipitation assays, Gaughan and coworkers were
able to show that TIP60, but not TIP60 HAT-domain
mutants, directly acetylates AR in vivo [19]. Alanine scanning
of the AR acetylation motif abolished coactivation by TIP60
in reporter gene assays providing further evidence that AR
acetylation by TIP60 is an important regulatory event [19].
Conversely, proteins that can directly deacetylate AR have
been reported. Histone deacetylase 1 (HDAC1) has been
shown to interact directly with the AR and repress AR activity
[19]. It was observed that HDAC1 interacted with a region
of the AR encompassing the DBD/LBD. Furthermore, the
deacetylase activity of HDAC1 was required for AR repres-
sion and although not proven, the authors suggest that direct
deacetylation of AR may result in a transcriptional switch
during AR-dependent gene expression [19]. In support of
this, both HDAC1 and TIP60 were found to occupy the PSA
promoter suggesting that the balance between acetylation
and deacetylation is crucial in AR gene regulation [19].
More definitively Sirtuin 1 (SIRT1), an NAD-dependent
Class III deacetylase, interacts with, deacetylates, and
represses AR activity [23]. A combination of protein-protein
interaction assays, use of SIRT1 inhibitors, and a catalytic
“dead” SIRT1 mutant indicated that SIRT1 could regulate
AR activity through direct deacetylation [23]. Interestingly,
it was observed in a mammalian-two-hybrid experiment
that SIRT1 abrogated p300-enhanced AR N/C-termini inter-
actions suggesting that this event may be disrupted by
deacetylation of AR hinge region [23]. Further experiments
utilising an AR acetylation-deficient mutant demonstrated
that this conferred resistance to SIRT1-dependent repression
and, complementing previous research whereby acetylation
enhanced prostate cancer cell line growth, it was found
that overexpression of SIRT1 led to a decrease in cellular
proliferation and colony formation. Strikingly, it was shown
that SIRT1 overexpression had no discernable eﬀect on
cell lines lacking AR indicating that growth inhibition was
directly linked to SIRT1-dependent AR deacetylation [23].
As outlined in Figure 1, the AR acetylation motif
is situated in the flexible hinge region, which connects
the structurally defined DNA-binding and ligand-binding
domains [3]. Recently, it has become clear that this region
impinges on a variety of steps in AR signalling including
DNA binding, transactivation, and nuclear localisation [24–
26]. Interestingly, this region contains the NLS (amino acids
617–635), which encompasses the acetylation motif. This
NLS has characteristics of a bipartite NLS such as that found
in nucleoplasmin, however, it interacts with importin-α in a
fashion that is mechanistically reminiscent of a classical or
monopartite NLS [27]. Mutations identified in this region
in patients with prostate cancer and androgen insensitivity
syndrome (AIS) were examined and shown to confer a ∼10–
30-fold lower aﬃnity for importin-α compared to wild-type
AR.When examined by confocal microscopy, the vast major-
ity of mutant AR proteins translocated more slowly from
cytoplasm to nucleus in the presence of ligand [27]. Of direct
interest here is a lysine to threonine substitution at amino
acid 630 (K630T), found in a patient with prostate cancer,
which changes the AR acetylation motif KLKK to TLKK
[28]. A combination of confocal microscopy, isothermal
calorimetry, and reporter assays indicated that ARK630T had
∼30-fold reduced aﬃnity for importin-α (KD = 140μM),
migrated more slowly into the nucleus upon hormone
stimulation, but paradoxically was more transcriptionally
active than ARWT[27]. Independently, Fu and coworkers
tested this mutant and found that ARK630T0020was resistant
to SIRT1-dependent repression [23]. These studies suggest a
link between acetylation, nuclear localisation, and prostate
cancer, but specific experiments to test this have not yet been
reported.
Recently, the concept of interdependent transcription
factor modifications has become widespread, particularly in
the context of p53 signalling [29], raising the question of
interdependency of acetylation and other posttranslational
modifications in AR signalling. On this topic, Pestell and
colleagues investigated the role of several kinases (AKT,
MAPKK, PKA) in signalling through AR wild-type and
AR acetylation mutants. It was observed that MAPKK
signalling through AR mutant proteins was unaltered, but
these mutants did aﬀect both cAMP and AKT signalling [30].
In support of this, inhibition of cAMP signalling led to an
increase of wild-type AR, but not an AR acetylation mutant,
on the PSA promoter. In addition, well-characterised AR
phosphorylation sites were targeted by site-directed muta-
genesis to investigate any eﬀect these phosphomutants may
have on AR acetylation. Indeed, one phosphorylation site
mutant (S94A) showed a decrease in transactivation of a
reporter gene in response to the HDAC inhibitor trichostatin
A (TSA) relative to wild-type AR [30]. Furthermore, of
the three main AR phosphoisoforms, acetylation mutants
lacked the hyperphosphorylated 114 kDa form, supporting
the hypothesis that acetylation and phosphorylation of AR
are interdependent events [30]. Additional experiments must
be performed to further characterise the interdependency
of AR posttranslational modifications and the functional
significance to signalling and gene expression.
3. Androgen Receptor Cofactors with
Histone-Acetylation Modifiying Activity
Exhaustive lists of AR coactivators, corepressors, and coreg-
ulators have been published previously [6, 13, 14, 31].
This section will focus on cofactors with histone-acetylation
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modifying activities that have been implicated in AR tran-
scriptional regulation.
The application of chromatin immunoprecipitation
(ChIP) to the study of protein-DNA interactions, epigenet-
ics, and transcriptional regulation has vastly increased our
knowledge of these processes. Indeed, recent advances in
ChIP-chip and ChIP-seq technologies have enabled genome-
wide mapping of binding sites for nuclear receptors, includ-
ing AR [32, 33]. Coregulators with HAT/HDAC activity
that have been characterised by ChIP to regulate AR-
regulated transcription include p300/CBP, the p160/SRC
family, P/CAF, TIP60, and HDAC1 [13].
The best-characterised AR coactivators are p300/CBP
and the p160/SRC proteins. These proteins augment the
transcriptional activity of multiple NRs and have been shown
to be overexpressed in prostate cancer [34–36]. Steroid
Receptor Coactivator-1 (SRC1) was identified as an SHR
coactivator by the O’Malley laboratory, and sequence and
domain interrogation studies led to the discovery that SRC1
contains an HAT domain and that this domain is integral
to SHR coactivation [37, 38]. In addition, p160 proteins
were further characterised as containing specific sites for
nuclear receptor interactions, a CBP interaction domain, and
individual activation domains [39]. Further experimentation
revealed that SRC1 could potentiate AR activity via separate
interactions with AR N- and C-termini suggesting that
SRC1 binding is an integral step in full transcriptional
activation of AR, possibly by recruiting further coactivators
such as p300/CBP [40–42]. CBP and the highly similar p300
were initially characterised as proteins with HAT activity
and thus able to regulate transcription [43–45]. Similar to
p160/SRC proteins, these factors contain a HAT domain, NR
binding sites but additionally sites important for interactions
with E1A and CREB proteins [44]. Initial characterisation
studies also proposed that these factors could recruit or bind
to p160/SRC proteins thus amplifying the transcriptional
response [42, 44, 46, 47].
More recently, ChIP-based investigations have reinforced
the idea that p160/SRC and p300/CBP factors are central
to AR transcriptional regulation. Investigating the response
of the AR-regulated gene encoding prostate-specific antigen
(PSA) to androgen, the Brown laboratory confirmed AR
binding to three AREs present in the PSA promoter; two
proximal to the transcriptional start site and one ARE present
in an enhancer region ∼4 kb upstream [48]. In addition to
AR binding, CBP and SRC2 bound to both enhancer and
promoter regions in the presence of hormone, in contrast
to HDAC1 and HDAC2 and corepressors SMRT and NCoR
which were able to bind PSA proximal promoter regions
only in the presence of the antiandrogen bicalutamide
[48]. Quantitative analysis by the laboratories of Ja¨nne and
Palvimo confirmed that SRC2 and p300 could interact with
these regions and provided evidence that AR could “load” on
enhancer elements to a much higher degree than at proximal
promoters. Furthermore, it was observed that diﬀerent load-
ing kinetics were present, both at enhancer and promoter
and between factors, implying another level of complexity
in gene regulation [49, 50]. Additional studies confirmed
the presence of multiple coactivators at gene enhancers
and promoters, and ChIP-3C established that chromosomal
“looping” between these regions could occur, functionally
linking distinct enhancer and promoter complexes [48, 51,
52].
TIP60, discussed previously as an AR factor acetyl
transferase (FAT), has more recently been found to cycle on
and oﬀ the PSA promoter and enhancer regions, suggesting
that this protein may regulate AR-dependent transcription
at the chromatin level either through direct acetylation
of AR or possibly through acetylation of chromatin [53].
Interestingly, by applying ChIP and re-ChIP techniques
the authors observed that the histone deacetylase HDAC1
and the ubiquitin ligase MDM2 (murine double-minute 2)
occupied the PSA promoter upon treatment with androgen,
suggesting these factors may bind simulatneously or even as
a complex. Furthermore, MDM2 and HDAC1 were found to
co-operatively attenuate AR-regulated transcription linking
ubiquitylation, acetylation and deacetylation processes. i.e.
(murine double-minute 2) should be after the first reference
to the protein [53].
Work from our own laboratory has indicated that
proteins belonging to the same family of co-repressors
may repress AR-target genes by diﬀerent mechanisms. We
have shown that Hairy/enhancer of split with YRPW-like
motif (HEY) proteins repress AR-dependent signalling in a
variety of cell lines [54, 55] (and paper submitted). Initially
discovered in a yeast-two-hybrid screen to interact with
SRC1, HEY1 was characterised as an AR corepressor. HEY1
is sensitive to a variety of HDAC inhibitors and treatment
with TSA resulted in de-repression of AR activity, suggesting
HEY1 repressed AR activity through the recruitment of class
I/II HDACs [55]. Similar experiments performed on HEYL,
a third member of the HEY family, indicated that class I/II
HDAC activity was not required for AR repression (paper
submitted), hence HEY proteins may employ a variety of
possible mechanisms to repress AR activity.
The AR regulates multiple and varied genes at the
level of transcription thus is reliant on the recruitment of
distinct coregulator complexes to fine-tune transcriptional
responses. It is apparent from numerous studies employing
ChIP that AR recruits proteins with both HAT and HDAC
activities, such as p160/SRC, p300/CBP, and HDAC1, to
achieve the desired control. The emergence of genome-
wide ChIP will allow the dissection and comparison of
transcriptional complexes at multiple genes and specific
patterns of histone modifications, which will further enhance
our knowledge of important coregulators.
4. Acetylation and Prostate Cancer
As stated above, direct acetylation of AR in response to
androgen stimulation increases AR activity, response element
binding, and cellular proliferation [17, 30, 56, 57]. The role of
acetylation in AR activity was confirmed using acetylation-
mimic mutants, which were found to interact with p300 to
a higher degree than wild-type AR. Additionally, a panel
of coactivators, such as SRC1 and TIP60, were found to
coactivate these mutant ARs more robustly than wild-type
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receptor. Furthermore, these mutants conferred a growth
advantage to tumour cells in vitro and in vivo suggesting
that AR acetylation may play an important role in the
development and/or progression of prostate cancer [16, 17,
56]. These data have been supported by the findings that
SIRT1, an NAD-dependent HDAC, can deacetylate AR and
reduce cellular proliferation and colony formation [23].
Androgens drive prostate tumour growth hence therapies
are directed towards reducing levels of circulating andro-
gens and AR activation via administration of luteinising-
hormone releasing hormone (LHRH) analogues and/or anti-
androgens. Patients generally respond well to treatment but
in the majority of cases tumours progress to the advanced,
androgen-independent/hormone-refractory stage of the dis-
ease. Several mechanisms can drive progression to androgen-
independent prostate cancer including amplification of AR,
altered levels of co-factors and somatic AR mutations that
result in promiscuous activation of the receptor by non-
androgenic ligands and growth factor pathways. [4, 58,
59]. Patients diagnosed with androgen-independent prostate
cancer have a median survival time of 12–18 months;
thus, it is important to develop new treatment strategies
to combat disease transition. One new development is
the reduction in levels of circulating adrenal androgens
using drugs such as Ketoconazole and Abiraterone, which
are p450 inhibitors targeting steroid biosynthesis pathways
[58, 60].
Several HDAC inhibitors are currently undergoing test-
ing in clinical trials including suberoylanilide hydroxamic
acid (SAHA), LBH589 and Depsipeptide, although results
suggest that these treatments have moderate eﬀects [58, 61].
It may seem paradoxical that HDAC inhibitors are used as
prostate cancer therapies since acetylation of AR increases
cellular proliferation as outlined above. However, it has
been proposed that HDAC inhibitors act via HDAC6 thus
acetylating HSP90, known to be central in AR folding and
ligand binding, or by sensitizing cells toDNAdamage [58, 62,
63]. A limited number of HAT inhibitors are in preclinical or
clinical trials, with p300/CBP and P/CAF-specific inhibitors
showing the most promising eﬀects [64, 65]. Curcumin,
a naturally occurring HAT inhibitor, has been shown to
inhibit CBP-dependent acetylation of histones and non-
histone proteins and seems to have a pro-apoptotic eﬀect on
prostate cancer cells in vitro and in vivo [64, 66, 67].
5. Concluding Remarks
Prostate cancer growth, in early stages, is driven by andro-
gens, and hence AR is central to disease formation and
progression. As a transcription factor, AR recruits and is
regulated by multiple proteins with a variety of enzymatic
functions, including proteins with the ability to modify
the acetylation status of chromatin and also the AR itself.
These modifications allow AR to directly and acutely regulate
the hormonal response, protein-protein interactions, tran-
scriptional complexes, and importantly cellular proliferation.
These observations, together with the findings that levels
of cofactors with HAT/HDAC activity are overexpressed in
patients with prostate cancer, have resulted in acetylation
becoming an important therapeutic target.
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